{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:49:31Z","timestamp":1789775371049,"version":"4.0.1"},"reference-count":7,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2021,4]]},"abstract":"\n Background:<\/jats:title>\n Cladribine is an antimetabolite used for the treatment of relapsing\u2013remitting multiple sclerosis. At present, there are no data available on its use in breastfeeding mothers and its transfer in human milk.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n We present a case of a lactating mother who donated her milk samples to study the transfer of cladribine following a 20-mg oral dose.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Analysis was done using liquid chromatography\u2013mass spectrometry.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n The relative infant dose calculated in this study was 3.06%.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n This is the first case report suggesting the transfer of cladribine in human milk in measurable quantities. However, caution should be advised during lactation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1352458520912173","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T04:46:49Z","timestamp":1591591609000},"page":"799-801","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Cladribine transfer into human milk: A case report"],"prefix":"10.1177","volume":"27","author":[{"given":"Palika","family":"Datta","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea I","family":"Ciplea","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany\/Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Rewers-Felkins","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Amarillo, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"Hale","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"bibr1-1352458520912173","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0695-9"},{"key":"bibr2-1352458520912173","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24936"},{"key":"bibr3-1352458520912173","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512446169"},{"key":"bibr4-1352458520912173","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70581-6"},{"key":"bibr5-1352458520912173","unstructured":"EMA. Mavenclad (cladribine) summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf (accessed 27 January 2020)."},{"key":"bibr6-1352458520912173","unstructured":"FDA. Mavenclad (cladribine) full prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022561s000lbl.pdf (2019, accessed 27 January, 2020)."},{"key":"bibr7-1352458520912173","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2013.791762"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458520912173","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458520912173","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458520912173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:02:48Z","timestamp":1777694568000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458520912173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1177\/1352458520912173"],"URL":"https:\/\/doi.org\/10.1177\/1352458520912173","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]}}}